These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26939845)

  • 21. To make progress in rare cancers, patients must lead the way.
    Dockser Marcus A
    J Clin Oncol; 2009 Jun; 27(16):2575-7. PubMed ID: 19414666
    [No Abstract]   [Full Text] [Related]  

  • 22. Specialized teams or specialist networks for rare cancers?
    Sandrucci S; Gatta G; Trama A; Dei Tos AP; Casali PG
    Eur J Surg Oncol; 2015 Sep; 41(9):1115-7. PubMed ID: 25936223
    [No Abstract]   [Full Text] [Related]  

  • 23. Alternative designs for clinical trials in rare diseases.
    Abrahamyan L; Feldman BM; Tomlinson G; Faughnan ME; Johnson SR; Diamond IR; Gupta S
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):313-331. PubMed ID: 27862920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A unifying strategy for clinical trials in rare urological malignancy.
    Nicholson S
    Nat Clin Pract Urol; 2008 Dec; 5(12):652-3. PubMed ID: 19015645
    [No Abstract]   [Full Text] [Related]  

  • 25. development of a therapeutic approach to rare cancers in children: the Children's Oncology Group experience.
    Pashankar FD; Rodriguez-Galindo C; Pappo A
    J Pediatr Hematol Oncol; 2012 May; 34 Suppl 2():S37-8. PubMed ID: 22525404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities.
    Krishnan ML; Berry-Kravis E; Capal JK; Carpenter R; Gringras P; Hipp JF; Miller MT; Mingorance A; Philpot BD; Pletcher MT; Rotenberg A; Tjeertes J; Wang PP; Willgoss T; de Wit MC; Jeste SS
    Nat Rev Drug Discov; 2021 Sep; 20(9):653-654. PubMed ID: 34002058
    [No Abstract]   [Full Text] [Related]  

  • 27. Rare cancers: the greatest inequality in cancer research and oncology treatment.
    Alvi MA; Wilson RH; Salto-Tellez M
    Br J Cancer; 2017 Oct; 117(9):1255-1257. PubMed ID: 28934760
    [No Abstract]   [Full Text] [Related]  

  • 28. Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov.
    Dechartres A; Riveros C; Harroch M; Faber T; Ravaud P
    JAMA Intern Med; 2016 Apr; 176(4):556-8. PubMed ID: 26954340
    [No Abstract]   [Full Text] [Related]  

  • 29. Rare cancers: a sea of opportunity.
    Boyd N; Dancey JE; Gilks CB; Huntsman DG
    Lancet Oncol; 2016 Feb; 17(2):e52-e61. PubMed ID: 26868354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A framework for applying unfamiliar trial designs in studies of rare diseases.
    Gupta S; Faughnan ME; Tomlinson GA; Bayoumi AM
    J Clin Epidemiol; 2011 Oct; 64(10):1085-94. PubMed ID: 21530171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare cancers: A network for better care.
    Sandrucci S; Gatta G
    Eur J Surg Oncol; 2019 Jan; 45(1):1-2. PubMed ID: 30041942
    [No Abstract]   [Full Text] [Related]  

  • 33. A quarter of patients with rarer cancers see GPs several times before referral.
    Mayor S
    BMJ; 2016 Feb; 352():i1198. PubMed ID: 26929277
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical research in rare diseases: new challenges, opportunities and ethical issues].
    Alfonso Farnós I; Alcalde Bezhold G
    An Pediatr (Engl Ed); 2020 Oct; 93(4):219-221. PubMed ID: 32921623
    [No Abstract]   [Full Text] [Related]  

  • 35. [Purposefulness of using fuzzy logic approaches in the rare disease clinical trials].
    Kiseleva TS; Pagava KI; Korinteli IA; Korinteli MG; Shonvadze DN
    Georgian Med News; 2011 Apr; (193):22-4. PubMed ID: 21617269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Networking in rare cancers: What was done, what's next.
    Frezza AM; Trama A; Blay JY; Casali PG
    Eur J Surg Oncol; 2019 Jan; 45(1):16-18. PubMed ID: 29685758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Methodology and management of clinical trials with small number of patients for rare diseases].
    Micallef J
    Presse Med; 2012 May; 41 Suppl 1():S32-4. PubMed ID: 22483773
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical trials and rare diseases.
    Lagakos SW
    N Engl J Med; 2003 Jun; 348(24):2455-6. PubMed ID: 12802033
    [No Abstract]   [Full Text] [Related]  

  • 39. Documenting rare disease data in China.
    Lin H; Long E; Chen W; Liu Y
    Science; 2015 Sep; 349(6252):1064. PubMed ID: 26339020
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial: Special issue on rare cancers.
    Sandler A; Reilly K; Widemann B
    Curr Probl Cancer; 2021 Aug; 45(4):100774. PubMed ID: 34304884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.